{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:18:05Z","timestamp":1794021485440,"version":"4.8.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106847","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:47:27Z","timestamp":1762645647000},"page":"106847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review"],"prefix":"10.1016","volume":"104","author":[{"given":"Salman","family":"Aljarallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-644X","authenticated-orcid":false,"given":"Ahmed","family":"AlThobaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abulaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"AlDosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Nassim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"AlNajashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Al","family":"Mutlaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtisam","family":"Althubaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaiza","family":"Alyafeai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Bunyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraj","family":"Makkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameelah","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"AlHajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Shahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser Al","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-9579","authenticated-orcid":false,"given":"Mohammed Al","family":"Jumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106847_bib0039","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD","volume":"11","author":"Akaishi","year":"2020","journal-title":"Front Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0026","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/aas.14386","article-title":"GRADE pearls and pitfalls-part 1: systematic reviews and meta-analyses","volume":"68","author":"Al Duhailib","year":"2024","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"8","key":"10.1016\/j.msard.2025.106847_bib0083","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.msard.2025.106847_bib0064","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"The Lancet Neurol."},{"issue":"22","key":"10.1016\/j.msard.2025.106847_bib0049","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106847_bib0003","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106847_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open."},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0038","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1177\/13524585231187120","article-title":"Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting","volume":"29","author":"Carnero Contentti","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106847_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"72","author":"Chang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","article-title":"Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"18","author":"Ciccarelli","year":"2019","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106847_bib0077","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3389\/fimmu.2020.01920","article-title":"Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors","volume":"11","author":"Clements","year":"2020","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0043","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2025.106847_bib0020","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet."},{"issue":"11","key":"10.1016\/j.msard.2025.106847_bib0045","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106847_bib0086","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurol.2024.01.008","article-title":"Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies","volume":"181","author":"Demuth","year":"2025","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"10.1016\/j.msard.2025.106847_bib0044","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","article-title":"Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder","volume":"101","author":"Demuth","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106847_bib0076","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10408444.2011.653487","article-title":"The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy","volume":"42","author":"DeSesso","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"issue":"3","key":"10.1016\/j.msard.2025.106847_bib0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10408444.2011.653487","article-title":"The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy","volume":"42","author":"DeSesso","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.msard.2025.106847_bib0051","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106847_bib0065","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209682","article-title":"Investigating the 2023 MOGAD criteria in children and adults with MOG-antibody positivity within and outside attacks","volume":"103","author":"Fonseca","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106847_bib0062","article-title":"Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria","volume":"11","author":"Forcadela","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2025.106847_bib0068","article-title":"Serum proteomics distinguish subtypes of NMO spectrum disorder and MOG antibody-associated disease and highlight effects of B-cell depletion","volume":"11","author":"Gawde","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0055","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0030","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106847_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clinic. Experiment. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106847_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.msard.2025.106847_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578709","article-title":"Prolonged corticosteroid therapy and steroid-sparing maintenance immunotherapy lower relapse risk in pediatric and adult MOGAD","volume":"407","author":"Hoshina","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.msard.2025.106847_bib0053","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0066","article-title":"MOG antibody\u2013Associated disease and Thymic Hyperplasia: from the National Multiple Sclerosis Society Case Conference Proceedings","volume":"10","author":"Hurtubise","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0007","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106847_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1594-1","article-title":"The history of neuromyelitis optica. Part 2:\u2018spinal amaurosis\u2019, or how it all began","volume":"16","author":"Jarius","year":"2019","journal-title":"J. Neuroinflammation."},{"issue":"8","key":"10.1016\/j.msard.2025.106847_bib0029","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Multiple Sclerosis J."},{"issue":"1","key":"10.1016\/j.msard.2025.106847_bib0084","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflammation."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0067","article-title":"Different complement activation patterns following C5 cleavage in MOGAD and AQP4-IgG+ NMOSD","volume":"11","author":"Kaneko","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2025.106847_bib0078","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106847_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat Options. Neurol."},{"key":"10.1016\/j.msard.2025.106847_bib0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fneur.2020.00860","article-title":"CADASIL vs. multiple sclerosis: is it misdiagnosis or concomitant? A case series","volume":"11","author":"Khan","year":"2020","journal-title":"Front Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106847_bib0046","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0054","first-page":"e1179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","volume":"9","author":"Kim","year":"2022","journal-title":"Neurology: Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106847_bib0017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106847_bib0010","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0071","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/1744-9987.14223","article-title":"Effectiveness and safety of therapeutic plasma exchange in neurological diseases: an 11-year report from a tertiary care center","volume":"29","author":"Korkmaz","year":"2025","journal-title":"Ther Apher. Dial."},{"key":"10.1016\/j.msard.2025.106847_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105941","article-title":"New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD","volume":"92","author":"Kosior","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106847_bib0031","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 seronegative neuromyelitis Optica spectrum disorder diagnostic criteria for patients with myelin oligodendrocyte glycoprotein IgG-associated disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"issue":"18","key":"10.1016\/j.msard.2025.106847_bib0042","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.3390\/jcm12185983","article-title":"Efficacy and safety of intravenous immunoglobulin treatment in selected neurological diseases\u2014One centre\u2019s experience based on the therapy of 141 patients","volume":"12","author":"Lasek-Bal","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9451","key":"10.1016\/j.msard.2025.106847_bib0006","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"The Lancet."},{"issue":"4","key":"10.1016\/j.msard.2025.106847_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0085","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/ene.15425","article-title":"Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation","volume":"29","author":"Li","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0059","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/00207454.2023.2238245","article-title":"Factors associated with disease relapse rate in the Neuromyelitis optica spectrum disorder","volume":"134","author":"Li","year":"2024","journal-title":"Int. J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106847_bib0087","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0072","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106847_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102484","article-title":"Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: a meta-analysis of real-world studies","volume":"46","author":"Luo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4\u20136","key":"10.1016\/j.msard.2025.106847_bib0050","first-page":"51","article-title":"Comparative analysis of treatment outcomes in patients with Neuromyelitis Optica Spectrum Disorder treated with rituximab, azathioprine, and mycophenolate mofetil: a systematic review and meta-analysis","volume":"19","author":"Magdalena","year":"2022","journal-title":"Innov. Clin. Neurosci."},{"issue":"4\u20136","key":"10.1016\/j.msard.2025.106847_bib0057","first-page":"51","article-title":"Comparative analysis of treatment outcomes in patients with Neuromyelitis Optica spectrum disorder treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: a systematic review and meta-analysis","volume":"19","author":"Magdalena","year":"2022","journal-title":"Innov. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0047","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209970","article-title":"Eculizumab in AQP4-IgG NMOSD: efficacy in the real world and potential warning of meningococcal vaccines","volume":"103","author":"Marignier","year":"2024","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2025.106847_bib0036","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137715","article-title":"Imaging surrogates of disease activity in neuromyelitis optica allow distinction from multiple sclerosis","volume":"10","author":"Matthews","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.msard.2025.106847_bib0018","article-title":"Challenges in the diagnosis and treatment of Neuromyelitis Optica spectrum disorders: a case report with a brief review of literature","volume":"6","author":"Morelli","year":"2018","journal-title":"J. Investig. Med. High Impact Case Rep."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0063","article-title":"MOG CNS autoimmunity and MOGAD","volume":"11","author":"Moseley","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106847_bib0082","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jocn.2022.08.020","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"105","author":"Nabizadeh","year":"2022","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2025.106847_bib0074","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early immunotherapy and longer corticosteroid treatment are associated with lower risk of relapsing disease course in pediatric MOGAD","volume":"10","author":"Nosadini","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0004","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Multiple Sclerosis J."},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106847_bib0028","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0058","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1007\/s00415-024-12426-w","article-title":"Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders","volume":"271","author":"Preziosa","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0048","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209888","article-title":"Eculizumab use in neuromyelitis optica spectrum disorders: routine clinical care data from a European cohort","volume":"103","author":"Ringelstein","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2025.106847_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518171","article-title":"Pregnancy in women with atypical hemolytic uremic syndrome","volume":"146","author":"Rondeau","year":"2022","journal-title":"Nephron"},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14737175.2024.2385941","article-title":"The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature","volume":"24","author":"Schir\u00f2","year":"2024","journal-title":"Expert Rev. Neurother."},{"issue":"7","key":"10.1016\/j.msard.2025.106847_bib0069","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2024-334863","article-title":"Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks","volume":"96","author":"Schwake","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiat."},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0081","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.msard.2025.106847_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101448","article-title":"Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry","volume":"38","author":"Shosha","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106847_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104062","article-title":"Saudi consensus recommendations on the management of neuromyelitis optica spectrum disorders (NMOSD)","volume":"66","author":"Shosha","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106847_bib0041","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J. Neurol."},{"issue":"18","key":"10.1016\/j.msard.2025.106847_bib0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody\u2013Associated disease","volume":"99","author":"Syc-Mazurek","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106847_bib0024","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jns.2017.08.3008","article-title":"Rituximub for neuromyelitis optica relapses: RIN-1 study","volume":"381","author":"Tahara","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2025.106847_bib0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"The Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0022","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106847_bib0012","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nature Rev. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106847_bib0027","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106847_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"11\u201312","key":"10.1016\/j.msard.2025.106847_bib0032","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/13524585231199819","article-title":"Double-negative neuromyelitis optica spectrum disorder","volume":"29","author":"Wu","year":"2023","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106847_bib0061","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu","year":"2024","journal-title":"Neurology."},{"issue":"22","key":"10.1016\/j.msard.2025.106847_bib0021","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106847_bib0056","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106847_bib0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"The Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:30:26Z","timestamp":1784345426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":87,"alternative-id":["S2211034825005899"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106847","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106847"}}